AbbVie
ABBV
#26
Rank
NZ$691.65 B
Marketcap
NZ$391.34
Share price
-1.15%
Change (1 day)
34.26%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) - Cash on Hand

Cash on Hand as of September 2025 : NZ$9.81 Billion

According to AbbVie's latest financial reports the company has NZ$9.81 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

AbbVie - Cash on Hand chart (from 2011 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31NZ$9.84 B-51.4%
2023-12-31NZ$20.26 B39.42%
2022-12-31NZ$14.53 B1.01%
2021-12-31NZ$14.39 B22.47%
2020-12-31NZ$11.75 B-80.18%
2019-12-31NZ$59.28 B393.28%
2018-12-31NZ$12.01 B-12.81%
2017-12-31NZ$13.78 B48.65%
2016-12-31NZ$9.27 B-24.51%
2015-12-31NZ$12.28 B14.93%
2014-12-31NZ$10.68 B-11.24%
2013-12-31NZ$12.04 B24.19%
2012-12-31NZ$9.69 B1058.81%
2011-12-31NZ$0.83 B5890.66%
2010-12-31NZ$13.96 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Pfizer
PFE
NZ$25.93 B 164.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$28.56 B 190.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$17.16 B 74.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$16.34 B 66.55%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$12.72 B 29.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$6.85 B-30.16%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$7.69 B-21.63%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$14.16 B 44.28%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$1.92 B-80.34%๐Ÿ‡บ๐Ÿ‡ธ USA